Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong John Schembri?

John Schembri

Vice President Finance and Administration

Global Blood Therapeutics, Inc.

HQ Phone:  (650) 741-7700

Email: j***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Global Blood Therapeutics, Inc.

400 East Jamie Court Suite 101

South San Francisco, California,94080

United States

Company Description

(GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an ... more.

Find other employees at this company (97)

Background Information

Employment History

Chief Financial Officer

BiPar Sciences , Inc.


Finance Team

Sirna Therapeutics , Inc.


Chief Financial Officer

StemPar Sciences


Similar Positions

COR Therapeutics , Inc.


Financial Management Positions

The Clorox Company


Web References(28 Total References)


Management Team | Investors | Global Blood Therapeutics

ir.globalbloodtx.com [cached]

John Schembri
Vice President, Finance and Administration John Schembri joined Global Blood Therapeutics as vice president, finance and administration in January 2014. Mr. Schembri has more than 25 years of experience as a finance executive in the biotechnology industry and previously served as chief financial officer of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million. Prior to that Mr. Schembri led the finance team at Sirna Therapeutics, which was acquired by Merck & Co. for $1.1 billion. He also served a key role in the $2 billion sale and integration of COR Therapeutics to Millennium Pharmaceuticals in 2001.


Senior Management | Global Blood Therapeutics

www.globalbloodtx.com [cached]

John Schembri
Vice President, Finance and Administration John Schembri joined Global Blood Therapeutics as vice president, finance and administration in January 2014. Mr. Schembri has more than 25 years of experience as a finance executive in the biotechnology industry and previously served as chief financial officer of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million. Prior to that Mr. Schembri led the finance team at Sirna Therapeutics, which was acquired by Merck & Co. for $1.1 billion. He also served a key role in the $2 billion sale and integration of COR Therapeutics to Millennium Pharmaceuticals in 2001.


www.sec.gov

John Schembri
John Schembri has served as our Vice President, Finance and Administration since January 2014. Prior to joining us, since June 2011, Mr. Schembri served as vice president and chief financial officer at StemPar Sciences, Inc. From July 2009 to May 2011, he was a consulting chief financial officer to early-stage companies. Prior to that, Mr. Schembri served as chief financial officer of BiPar Sciences, Inc., from January 2007 until it was acquired by sanofi-aventis S.A. in 2009. Prior to joining BiPar Sciences, Mr. Schembri led the finance team at Sirna Therapeutics, Inc., a biotechnology company, from January 2006 until it was acquired by Merck & Co., Inc. in December 2006. He also served a key role in the $2 billion sale and integration of COR Therapeutics Inc., a biopharmaceutical company, to Millennium Pharmaceuticals, Inc. in 2001. Mr. Schembri holds a B.S. in business administration from California State Polytechnic University, San Luis Obispo.


www.sec.gov


0001375857 Schembri John C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks


Leadership Team - Global Blood Therapeutics

www.globalbloodtx.com [cached]

John Schembri
Vice President, Finance and Administration John Schembri joined Global Blood Therapeutics as vice president, finance and administration in January 2014. Mr. Schembri has more than 25 years of experience as a finance executive in the biotechnology industry and previously served as chief financial officer of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million. Prior to that Mr. Schembri led the finance team at Sirna Therapeutics, which was acquired by Merck & Co. for $1.1 billion. He also served a key role in the $2 billion sale and integration of COR Therapeutics to Millennium Pharmaceuticals in 2001.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory